The European Medicines Agency (EMA) estimated the prevalence of<unk>  at the time of granting orphan drug designation for<unk>  in 2004 at 1.5 in 100,000 people, corresponding to a current prevalence of about 8,000 in the EU, 5,000 in the U.S., and 2,000 in Japan. Patients who lack chronic heart failure and those who respond well to prednisone or a similar drug have a good prognosis. However, the mortality rate rises in patients with anaemia, chromosomal abnormalities or a very high white blood cell count.
Hypereosinophilic syndrome
Clonal hypereosinophilia
Tropical eosinophilia
Eosinophilic esophagitis
Familial eosinophilia
Mast cell activation syndrome
CREST syndrome
IgA vasculitis